Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as the company’s CVRM hub.

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...

The first life science tenant at Harvard’s new Allston development is a research center that could eventually become home to ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report) and Roche ...